68788-7075 : 12 Hour Original Nasal Decongestant 50 mg/100ml Nasal Liquid


NDC68788-7075
Labeler: Preferred Pharmaceuticals Inc.
Product Type: Human OTC Drug
Drug Name:  12 Hour Original Nasal Decongestant
Dosage Form: Nasal Liquid
Application #: part341
Rev. Date: 


NDC Package Codes:

  • 68788-7075-3: 1 BOTTLE, SPRAY IN 1 CARTON (68788‑7075‑3) > 30 ML IN 1 BOTTLE, SPRAY

Active Ingredients:

  • Oxymetazoline Hydrochloride

Dosage Strength:

  • 50 mg/100mL

Related Products:

Based on records with the same trade name.
  • 11527-140 12 Hour Original Nasal Decongestant 50 mg/100ml Nasal Liquid by Faria LLC Dba Sheffield Pharmaceutical
  • 67091-378 12 Hour Original Nasal Decongestant 50 mg/100ml Nasal Liquid by Winco Foods LLC
  • 67751-209 12 Hour Original Nasal Decongestant 50 mg/100ml Nasal Liquid by Navajo Manufacturing Company Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 68788-7075 QR Code

< Prev: 68788-7074Next: 68788-7076 >

Related Discussions:

oxymetazoline eye drops
I think they are selling Visine LR on the internet, but it is very expensive. It is the only gtts that work for me. Have... 2 replies
Oxymetazoline nasal drops could not sleep
Recently bought Oxymetazoline nasal spray. I have COPD emphysema. I spent the whole night coughing with no sleep. Has an... 1 reply
eye drops with oxymetazoline
replacement for Visine LR ## PLEASE IF THERE IS A REPLACEMENT FOR VLR, LET US KNOW ALL THE DETAILS OF THE EYE DROPS ASAP... 111 replies
Replacement for Visine L.R. w/oxymetazoline.
Opcon A eye drops work well for a short time. I haven't found any eye drops to replace Visine L.R. that have the las... 2 replies




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.